Aviso Wealth Management Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Aviso Wealth Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,269 shares of the biopharmaceutical company's stock after selling 24,757 shares during the period. Aviso Wealth Management's holdings in Pfizer were worth $1,274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. Westpac Banking Corp grew its stake in shares of Pfizer by 38.4% during the 4th quarter. Westpac Banking Corp now owns 102,671 shares of the biopharmaceutical company's stock valued at $2,724,000 after purchasing an additional 28,473 shares during the period. World Investment Advisors increased its position in shares of Pfizer by 5.6% during the 4th quarter. World Investment Advisors now owns 134,378 shares of the biopharmaceutical company's stock valued at $3,565,000 after purchasing an additional 7,113 shares during the last quarter. Finally, Arete Wealth Advisors LLC lifted its stake in shares of Pfizer by 34.0% in the 4th quarter. Arete Wealth Advisors LLC now owns 86,772 shares of the biopharmaceutical company's stock worth $2,299,000 after purchasing an additional 22,013 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $23.49 on Friday. The company has a market cap of $133.55 billion, a P/E ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm's fifty day moving average is $24.36 and its two-hundred day moving average is $24.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Analysts Set New Price Targets

Several brokerages recently issued reports on PFE. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. BMO Capital Markets decreased their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Bank of America lifted their target price on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.